Pediatric multiple sclerosis (MS) is a rare multiple sclerosis variant characterized by the onset of multiple sclerosis (i.e. one or multiple episodes of clinical CNS symptoms consistent with acquired...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding pediatric multiple sclerosis is largely due to its rarity, as it affects a small population of children and adolescents. This has resulted in fewer systematic clinical studies and a lack of comprehensive data on its genetic basis and clinical features. Ongoing research is crucial to better understand this condition and improve patient outcomes.
To navigate pediatric multiple sclerosis, seek a neurologist with expertise in pediatric demyelinating diseases. Consider reaching out to the Tanner Foundation for Multiple Sclerosis for support and resources. You may also explore participation in clinical trials, which can provide access to new therapies and contribute to research. For more information on available resources, visit GARD at rarediseases.info.nih.gov. Engaging with patient organizations can also be beneficial in connecting with others facing similar challenges.
There are currently three orphan drugs designated for pediatric multiple sclerosis: Glyeraldehyde-3-phosphate dehydrogenase, recombinant ovine interferon tau, and T cell receptor (TCR) peptide vaccines. Additionally, there are 17 active clinical trials exploring various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pediatric%20multiple%20sclerosis. This research holds promise for developing effective treatments in the future.
Actionable guidance for navigating care for pediatric multiple sclerosis
To navigate pediatric multiple sclerosis, seek a neurologist with expertise in pediatric demyelinating diseases. Consider reaching out to the Tanner Foundation for Multiple Sclerosis for support and resources. You may also explore participation in clinical trials, which can provide access to new therapies and contribute to research. For more information on available resources, visit GARD at rarediseases.info.nih.gov. Engaging with patient organizations can also be beneficial in connecting with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the pediatric multiple sclerosis community
Helpful links for rare disease information and support
The limited documentation surrounding pediatric multiple sclerosis is largely due to its rarity, as it affects a small population of children and adolescents. This has resulted in fewer systematic clinical studies and a lack of comprehensive data on its genetic basis and clinical features. Ongoing research is crucial to better understand this condition and improve patient outcomes.
To navigate pediatric multiple sclerosis, seek a neurologist with expertise in pediatric demyelinating diseases. Consider reaching out to the Tanner Foundation for Multiple Sclerosis for support and resources. You may also explore participation in clinical trials, which can provide access to new therapies and contribute to research. For more information on available resources, visit GARD at rarediseases.info.nih.gov. Engaging with patient organizations can also be beneficial in connecting with others facing similar challenges.
There are currently three orphan drugs designated for pediatric multiple sclerosis: Glyeraldehyde-3-phosphate dehydrogenase, recombinant ovine interferon tau, and T cell receptor (TCR) peptide vaccines. Additionally, there are 17 active clinical trials exploring various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pediatric%20multiple%20sclerosis. This research holds promise for developing effective treatments in the future.
Actionable guidance for navigating care for pediatric multiple sclerosis
To navigate pediatric multiple sclerosis, seek a neurologist with expertise in pediatric demyelinating diseases. Consider reaching out to the Tanner Foundation for Multiple Sclerosis for support and resources. You may also explore participation in clinical trials, which can provide access to new therapies and contribute to research. For more information on available resources, visit GARD at rarediseases.info.nih.gov. Engaging with patient organizations can also be beneficial in connecting with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the pediatric multiple sclerosis community
Helpful links for rare disease information and support
The limited documentation surrounding pediatric multiple sclerosis is largely due to its rarity, as it affects a small population of children and adolescents. This has resulted in fewer systematic clinical studies and a lack of comprehensive data on its genetic basis and clinical features. Ongoing research is crucial to better understand this condition and improve patient outcomes.
To navigate pediatric multiple sclerosis, seek a neurologist with expertise in pediatric demyelinating diseases. Consider reaching out to the Tanner Foundation for Multiple Sclerosis for support and resources. You may also explore participation in clinical trials, which can provide access to new therapies and contribute to research. For more information on available resources, visit GARD at rarediseases.info.nih.gov. Engaging with patient organizations can also be beneficial in connecting with others facing similar challenges.
There are currently three orphan drugs designated for pediatric multiple sclerosis: Glyeraldehyde-3-phosphate dehydrogenase, recombinant ovine interferon tau, and T cell receptor (TCR) peptide vaccines. Additionally, there are 17 active clinical trials exploring various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pediatric%20multiple%20sclerosis. This research holds promise for developing effective treatments in the future.
Actionable guidance for navigating care for pediatric multiple sclerosis
To navigate pediatric multiple sclerosis, seek a neurologist with expertise in pediatric demyelinating diseases. Consider reaching out to the Tanner Foundation for Multiple Sclerosis for support and resources. You may also explore participation in clinical trials, which can provide access to new therapies and contribute to research. For more information on available resources, visit GARD at rarediseases.info.nih.gov. Engaging with patient organizations can also be beneficial in connecting with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the pediatric multiple sclerosis community
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Patient organization involved in 1 clinical trial(s) for rare diseases.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 5 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.